Osteoporosis leads to 1.5 million fractures per year In the UK, one woman in three and at least one man in twelve will develop osteoporosis in their lifetime. From middle age onwards, osteoporosis is actually more common in women than heart attacks, strokes, diabetes, rheumatoid arthritis and breast cancer.
Osteoporosis is called the ‘silent disease’ because you cannot see or feel your bones losing density. It is a condition characterised by a degenerative thinning of bones, which can lead to chest pains and fractures. Bone degeneration starts out slowly, usually around the age of 35, and accelerates in women after menopause, and in men after the age of 65. Over the age of 60, 30% of women and 10% of men will have the disease, with half the population over 70 being affected. British women over 45 sufferapproximately 200,000 fractures annually.
This test requires a single urine sample to measure the rate of bone turnover, which is an important predictor for the risk of developing osteoporosis. It is important to identify individuals currently losing bone at an accelerated rate so that effective treatment can begin before significant bone loss has occurred.
Sufferers frequently describe a dull uncomfortable, achy feeling, which is not necessarily localised to any one area, or chronic back pain with muscle spasms along one or both sides of the spine. These pains worsen with sitting and standing, and are relieved by lying down. One simple indicator of osteoporosis is a decrease in height. Another warning sign may be tooth loss, because gum inflammation can result from bone degeneration.
Risk factors for osteoporosis
- Family history of osteoporosis
- White or Asian race
- Poor diet and smoking
- Excessive alcohol intake
- Gastric/ small bowel resection
- Lack of exercise
- Long term steroid therapy
- Long term use of anticonvulsants
- Post menopause and premature menopause
- Short stature and small bones
- High intake of carbonated drinks
- Old age
- Chronic stress
- History of fractures
- Hormonal imbalances including hyperparathyroidism and hyperthyroidism
Osteoporosis risk assessment enables you and your practitioner to
- Identify risk of developing osteoporosis.
- Identify rate of bone breakdown.
- Monitor effectiveness of supplement, dietary or anti-resorptive therapy
What is being measured
This test measures the breakdown products of bone that are excreted in the urine Presence in the urine of higher than normal amounts indicate a rapid rate of bone loss.
- Urinary pyridinium crosslinks
- (PYD + DPD)
Age range this test is suitable for
1st morning urine sample
Before taking the test
No special preparation required
See instructions inside test kit for urine collection
Turn Around Time
All sample reports are for representational and educational purposes only. Biomarkers, references ranges, results, and all other data may differ from actual reports. All data included in no way represents an actual patient. Any comparisons of results to actual patients, is completely incidental.